ArticleFrontiers in immunology2026
Leucine, autoimmune diseases, and circulating mediators shape the causal landscape of lymphoid malignancies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: While genetic abnormalities underlying lymphoid malignancies (LM) are well-characterized, the environmental and metabolic determinants driving LM remain largely unexplored. Autoimmune diseases are known risks, yet the specific circulating mediators and potential protective dietary factors linking these conditions to LM require systematic elucidation. Objectives: This study aimed to comprehensively screen for causal risk factors of LM, identify the metabolic mediators bridging autoimmune diseases and LM, and validate the therapeutic potential of leucine as a protective factor. Methods: We conducted a systematic Mendelian randomization analysis using 10,090 GWAS traits obtained from the IEU OpenGWAS project, including 2,568 plasma proteins and 662 plasma metabolites, to identify potential causal determinants of LM. Findings were validated using the large-scale UK Biobank cohort (n=502,175) and further supported by multi-omics data (plasma proteomics (Olink; n = 53,014) and metabolomics (NMR; 486,813)) within the same population. Mechanisms were further verified via Results: We identified autoimmune diseases-specifically hyperthyroidism and membranous nephropathy, as novel risk factors for LM. Mediation analysis revealed that promotilin, monounsaturated fatty acids (MUFAs), and glucose serves as key circulating mediators driving this risk. Conversely, leucine emerged as a protective metabolic factor. High-leucine conditions suppressed proliferation and induced apoptosis in LM cell lines, while dietary leucine supplementation prolonged survival and alleviated anemia and thrombocytopenia in the BCP-ALL mouse models. In patient cohorts, higher plasma leucine levels were associated with improved outcomes in non-Ph B-ALL and prolonged survival in CAR-T-treated B-cell lymphoma patients. Mechanistically, leucine exposure induced metabolic reprogramming characterized by the suppression of lipid biosynthesis pathways and reduced Conclusion: Autoimmune diseases increase LM susceptibility through specific metabolic mediators. Leucine functions as a potent protective agent and prognostic biomarker. These findings suggest that dietary leucine supplementation represents a promising and readily translatable therapeutic strategy for managing LM and enhancing CAR-T therapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.